

Pharmaceuticals UltraSector ProFund

Service Class PHPSX



Semi-annual Shareholder Report – January 31, 2025

Fund Overview

This Semi-annual shareholder report contains important information about the Pharmaceuticals UltraSector ProFund (the "Fund") for the period of August 1, 2024 to January 31, 2025. You can find additional information about the Fund at www.profunds.com/shareholder-reports. You can also request this information by contacting us at 888-776-3637.

What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Service Class	\$143	2.78%

Fund Statistics	
Net Assets	\$2,787,286
Number of Holdings*	51
Net Investment Advisory Fees	\$1,600
Portfolio Turnover	73%

* No. of Holdings excludes any derivatives and collateral for securities loaned.

Largest Sector Weights	
Sector	
Pharmaceuticals	100%

Market Exposure	
Investment Type	% of Net Assets
Equity Securities	85%
S&P Pharmaceuticals Select Industry Index Swap Agreements	66%
Total	151%

Largest Equity Holdings	
Holding	% of Net Assets
Intra-Cellular Therapies, Inc.	4.5%
Royalty Pharma PLC - Class A	3.7%
Corcept Therapeutics, Inc.	3.3%
Axsome Therapeutics, Inc.	3.2%
Pfizer, Inc.	3.1%

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and instruments used for cash management.

Pharmaceuticals UltraSector ProFund

Service Class PHPSX

Semi-annual Shareholder Report – January 31, 2025

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, www.profunds.com/shareholder-reports, or upon request, by calling 888-776-3637.

